FluoroPharma files IND for CardioPET

By Elaine Rigoli

Tampa, Fla., June 13 - FluoroPharma, Inc. has filed its first Investigational New Drug application for the CardioPET molecular imaging agent.

CardioPET is a novel cardiac viability imaging agent in development that allows acute and chronic coronary artery disease to be assessed while patients are at rest, according to a news release.

About 20% of patients with suspected coronary artery disease cannot undergo sufficient physical exertion on a treadmill, which is a standard test to assess the disease.

FluoroPharma said it plans to demonstrate that CardioPET may be an accurate alternative to standard treadmill stress-testing in these patients.

Boston-based FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.